| 货号 | 规格 | 价格 | 上海 | 北京 | 珠海 | 重庆 | 武汉 | 购买数量 |
|---|---|---|---|---|---|---|---|---|
V45751-5mg |
≥98% | ￥590.00 |
货期：3-5天 | - | - | - | - |
|
V45751-10mg |
≥98% | ￥990.00 |
货期：3-5天 | - | - | - | - |
|
V45751-25mg |
≥98% | ￥1990.00 |
货期：3-5天 | - | - | - | - |
|
V45751-50mg |
≥98% | ￥3190.00 |
货期：3-5天 | - | - | - | - |
|
V45751-100mg |
≥98% | ￥4990.00 |
货期：3-5天 | - | - | - | - |
|
| 产品描述： | PCSK9-IN-11 (compound 5r) is a potent and orally active PCSK9 inhibitor. PCSK9-IN-11 exhibits PCSK9 transcriptional inhibitory activity in HepG2 cells, with an IC50 of 5.7 μM. PCSK9-IN-11 increases LDL receptor (LDLR) protein level. PCSK9-IN-11 can be used for atherosclerosis research. | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 体外研究： | PCSK9-IN-11 (compound 5r) (0-25 μM, 24 h) significantly decreases PCSK9 protein level and increases LDLR expression in a dose dependent manner. | ||||||||||||||||||||
| 体内研究： | PCSK9-IN-11 (compound 5r) (0-1000 mg/kg, IG, once) exhibits a good in vivo safety feature with the halflethal dose (LD50) value of over 1000 mg/kg. PCSK9-IN-11 (30 mg/kg, IG, once a day for 8 weeks) significantly suppresses hepatic PCSK9 expression and 웿 |
||||||||||||||||||||
| 参考文献： | 1. Qiao MQ, et al. Structure-activity relationship and biological evaluation of xanthine derivatives as PCSK9 inhibitors for the treatment of atherosclerosis. Eur J Med Chem. 2022 Dec 26;247:115047. |
||||||||||||||||||||
| 保存条件： | 2-8°C, 避光 | ||||||||||||||||||||
| 配置溶液浓度参考： |
|
||||||||||||||||||||
| 注意： | 部分产品我司仅能提供部分信息，我司不保证所提供信息的权威性，仅供客户参考交流研究之用。 |
上海工商
沪公网安备 31011702002021号
危险品化学品经营许可证（不带存储）
营业执照(三证合一)
北京